Liquidia Co. (NASDAQ:LQDA) Receives Consensus Recommendation of "Buy" from Brokerages

Liquidia Co. (NASDAQ:LQDA - Get Free Report) has been given an average recommendation of "Buy" by the nine ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $25.38.

LQDA has been the subject of a number of research analyst reports. HC Wainwright restated a "buy" rating and set a $29.00 price objective on shares of Liquidia in a research report on Thursday, November 14th. Wells Fargo & Company initiated coverage on Liquidia in a research report on Friday, December 20th. They set an "overweight" rating and a $20.00 price objective for the company. Finally, Needham & Company LLC restated a "buy" rating and set a $19.00 price objective on shares of Liquidia in a research report on Thursday, January 9th.

Liquidia Price Performance

Shares of Liquidia stock traded up $0.34 during trading on Friday, reaching $15.53. 705,707 shares of the stock traded hands, compared to its average volume of 879,469. The company has a market capitalization of $1.31 billion, a price-to-earnings ratio of -9.53 and a beta of 0.07. The business has a fifty day simple moving average of $14.09 and a two-hundred day simple moving average of $11.76. Liquidia has a 52-week low of $8.26 and a 52-week high of $16.99.

Remove Ads

Insider Buying and Selling

In other Liquidia news, insider Rajeev Saggar sold 2,445 shares of the firm's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $13.00, for a total value of $31,785.00. Following the completion of the sale, the insider now owns 267,943 shares of the company's stock, valued at $3,483,259. This trade represents a 0.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Michael Kaseta sold 23,370 shares of the firm's stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total transaction of $275,298.60. Following the completion of the sale, the chief financial officer now directly owns 401,755 shares of the company's stock, valued at approximately $4,732,673.90. The trade was a 5.50 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 71,245 shares of company stock worth $843,326. Corporate insiders own 30.10% of the company's stock.

Institutional Trading of Liquidia

Several institutional investors have recently added to or reduced their stakes in LQDA. Creative Planning bought a new stake in shares of Liquidia during the third quarter valued at approximately $170,000. Intech Investment Management LLC bought a new position in Liquidia in the third quarter worth approximately $195,000. Charles Schwab Investment Management Inc. raised its stake in Liquidia by 144.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company's stock worth $3,903,000 after buying an additional 230,820 shares in the last quarter. BNP Paribas Financial Markets raised its stake in Liquidia by 735.1% in the third quarter. BNP Paribas Financial Markets now owns 140,190 shares of the company's stock worth $1,402,000 after buying an additional 123,402 shares in the last quarter. Finally, Acuta Capital Partners LLC bought a new position in Liquidia in the third quarter worth approximately $735,000. Institutional investors own 64.54% of the company's stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).